Spero Therapeutics Free Cash Flow (FCF) History (SPRO)

Spero Therapeutics reported −$86.0M in free cash flow for fiscal 2020, a decrease of $35.7M from the previous fiscal year, with a free cash flow margin of −33344.57%.

View full Spero Therapeutics company overview

Spero Therapeutics free cash flow by year

Spero Therapeutics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20202020-12-31−$86.0M−$35.7M−33344.57%
20192019-12-31−$50.3M−$8.3M−1061.45%
20182018-12-31−$42.1M−$2.9M−1060.54%
20172017-12-31−$39.1M−$9.3M−1977.67%
20162016-12-31−$29.8M−$19.9M−8892.24%
20152015-12-31−$9.8M

Spero Therapeutics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from −$9.8M to −$86.0M, a net decrease of $76.2M. Spero Therapeutics's latest reported quarter, Q3 2021, generated −$5.0M in free cash flow, an increase of $18.5M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Spero Therapeutics filings at SEC.gov ↗